People · Operator
Named in public records as an officer, director or promoter · active 2016–2021 · Biotechnology, Pharmaceuticals, Other Technology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Keros Therapeutics, Inc. | — | Biotechnology | Series C | $78.5M | $2.3B | 2020 |
| Microbion Corp | — | Pharmaceuticals | Series B | $45.7M | $329.0M | 2016 |
| Variantyx Inc. | — | Other Technology | Series B | $15.6M | $380.1M | 2021 |
| Bioarray Genetics, Inc. | — | Other Health Care | Series A | $6.7M | $105.3M | 2017 |
Zafrira Avnur at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Zafrira Avnur on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Patrick O'Neill | 1 | 14 |
| Alon Lazarus | 1 | 7 |
| Pauline Murphy | 1 | 6 |
| Julius Knowles | 1 | 5 |
| Una Ryan | 1 | 4 |
| Henry Kay | 1 | 3 |
| Ran Nussbaum | 1 | 3 |
| Julia Levy | 1 | 3 |
| JASBIR SEEHRA | 1 | 2 |
| Nima Farzan | 1 | 2 |
| Hillel Bachrach | 1 | 2 |
| Jason Harmon | 1 | 2 |
| Pamela Layton | 1 | 2 |
| Jared Carney | 1 | 1 |
| Steven Schellong | 1 | 1 |
| Karim Lalji | 1 | 1 |
| Brett Baker | 1 | 1 |
| Frank Kerins | 1 | 1 |
| Ran S. Nussbaum | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.